The bill would add coverage under Medicare for treatments for dialysis-related amyloidosis that are approved by the Food and Drug Administration and provided in a dialysis facility. Coverage would also include supplies and services needed for those treatments. The bill would require separate payment for these treatments at 100% of their reasonable charges, rather than including them in a broader dialysis payment. The changes would take effect when the bill becomes law.
If you have Medicare and receive an eligible treatment in a dialysis facility, the bill would provide Medicare coverage for the treatment and necessary related supplies and services. The text does not specify patient eligibility details or any patient cost-sharing rules.
The bill sets payment at 100% of reasonable charges for covered treatments and related services. It does not provide an estimate of total costs or explain any costs patients may owe.
No publicly available information.
No publicly available information.